These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 10500056)

  • 1. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
    Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ
    Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
    Asakura H; Yao T; Matsui T; Koganei K; Fukushima T; Takazoe M; Hobara R; Nakano H; Okamura S; Matsueda K; Kashida H; Makiyama K; Hiwatashi N; Kashiwagi K; Hibi T
    J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
    Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
    Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.
    Buhl SS; Steenholdt C; Brynskov J; Thomsen OØ; Bendtzen K; Ainsworth MA
    BMJ Open; 2014 Dec; 4(12):e005887. PubMed ID: 25524543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.
    Mortimore M; Gibson PR; Selby WS; Radford-Smith GL; Florin TH;
    Intern Med J; 2001 Apr; 31(3):146-50. PubMed ID: 11478343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
    D'haens G; Van Deventer S; Van Hogezand R; Chalmers D; Kothe C; Baert F; Braakman T; Schaible T; Geboes K; Rutgeerts P
    Gastroenterology; 1999 May; 116(5):1029-34. PubMed ID: 10220494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
    Rutgeerts PJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease.
    Rodrigo L; Pérez-Pariente JM; Fuentes D; Cadahia V; García-Carbonero A; Niño P; de Francisco R; Tojo R; Moreno M; González-Ballina E
    Rev Esp Enferm Dig; 2004 Aug; 96(8):548-54; 554-8. PubMed ID: 15449986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
    Sandborn WJ; Feagan BG; Hanauer SB; Present DH; Sutherland LR; Kamm MA; Wolf DC; Baker JP; Hawkey C; Archambault A; Bernstein CN; Novak C; Heath PK; Targan SR;
    Gastroenterology; 2001 May; 120(6):1330-8. PubMed ID: 11313302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.